Literature DB >> 15260370

Cognitive dysfunction and depression during treatment with interferon-alpha and chemotherapy.

Randall S Scheibel1, Alan D Valentine, Susan O'Brien, Christina A Meyers.   

Abstract

Trials with interferon-alpha (IFN-alpha) have provided contradictory findings regarding the presence of cognitive side effects. The development of depression in some patients also raises questions about whether cognitive dysfunction might be secondary to an organic, interferon-induced mood disorder. Thirty patients with chronic myelogenous leukemia were examined before and during treatment with IFN-alpha alone or IFN-alpha and chemotherapy. Increased depressive symptoms and declines in information processing and executive functions were observed, but depression alone could not account for cognitive dysfunction. There was some evidence suggesting that exposure to chemotherapy and higher cumulative IFN-alpha dose may contribute to cognitive impairment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15260370     DOI: 10.1176/jnp.16.2.185

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  25 in total

Review 1.  Candidate mechanisms for chemotherapy-induced cognitive changes.

Authors:  Tim A Ahles; Andrew J Saykin
Journal:  Nat Rev Cancer       Date:  2007-03       Impact factor: 60.716

2.  Complement receptor 2 is expressed in neural progenitor cells and regulates adult hippocampal neurogenesis.

Authors:  Maiko Moriyama; Takeshi Fukuhara; Markus Britschgi; Yingbo He; Ramya Narasimhan; Saul Villeda; Hector Molina; Brigitte T Huber; Mike Holers; Tony Wyss-Coray
Journal:  J Neurosci       Date:  2011-03-16       Impact factor: 6.167

3.  The recombinant vaccinia virus gene product, B18R, neutralizes interferon alpha and alleviates histopathological complications in an HIV encephalitis mouse model.

Authors:  Cari Fritz-French; Ramzi Shawahna; Jennifer E Ward; Leonard E Maroun; William R Tyor
Journal:  J Interferon Cytokine Res       Date:  2014-02-24       Impact factor: 2.607

4.  Electrochemical Measurement of Dopamine Release and Uptake in Zebrafish Following Treatment with Carboplatin.

Authors:  Thomas M Field; Mimi Shin; Chase S Stucky; Joseph Loomis; Michael A Johnson
Journal:  Chemphyschem       Date:  2018-04-25       Impact factor: 3.102

Review 5.  Investigation of cognitive impairments in people with brain tumors.

Authors:  Anna Rita Giovagnoli
Journal:  J Neurooncol       Date:  2012-03-06       Impact factor: 4.130

Review 6.  Neurobehavioral effects of interferon therapy.

Authors:  Alan D Valentine; Christina A Meyers
Journal:  Curr Psychiatry Rep       Date:  2005-10       Impact factor: 5.285

7.  Neuropsychological care and rehabilitation of cancer patients with chemobrain: strategies for evaluation and intervention development.

Authors:  Pascal Jean-Pierre; Douglas Johnson-Greene; Thomas G Burish
Journal:  Support Care Cancer       Date:  2014-03-27       Impact factor: 3.603

Review 8.  Cognitive Impairment Associated with Cancer: A Brief Review.

Authors:  J Cara Pendergrass; Steven D Targum; John E Harrison
Journal:  Innov Clin Neurosci       Date:  2018-02-01

9.  Early antiretroviral treatment prevents the development of central nervous system abnormalities in simian immunodeficiency virus-infected rhesus monkeys.

Authors:  Maria Cecilia G Marcondes; Claudia Flynn; Salvador Huitron-Rezendiz; Debbie D Watry; Michelle Zandonatti; Howard S Fox
Journal:  AIDS       Date:  2009-06-19       Impact factor: 4.177

10.  The systemic inflammatory response and its relationship to pain and other symptoms in advanced cancer.

Authors:  Barry J Laird; Donald C McMillan; Peter Fayers; Kenneth Fearon; Stein Kaasa; Marie T Fallon; Pål Klepstad
Journal:  Oncologist       Date:  2013-08-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.